This morning, AbbVie revealed positive top-line results from the Phase 3 SELECT-COMPARE clinical trial evaluating upadacitinib in rheumatoid arthritis.
Mathew Shanley
Advertisement
Articles by Mathew Shanley
Advertisement
Latest Updated Articles
Phase 3 of Rheumatoid Arthritis Drug Meets Primary and Secondary EndpointsPublished: April 9th 2018 | Updated:
Advertisement
Advertisement